Type of information: Loan
Company: Tetraneuron (Spain)
Investors: Valencian Institute of Finance (Spain) FEDER (EU)
Amount: 1million €
Funding type: loan
Planned used: With this new line of funding, Tetraneuron will advance both in the preclinical development of TET-E2F4DN gene therapy for Alzheimer’s disease and opening a new line of research around glaucoma.Tetraneuron expects to obtain FDA approval for its preclinical roadmap and the related clinical design.
Others: • On December 27, 2021, Tetraneuron, a Spanish company developing a multifactorial gene therapy for the treatment of Alzheimer’s disease and other neurodegenerative diseases announced that the company will receive 1M€ of financing through the line of disruptive project loans, co-financed by the Valencian Institute of Finance and FEDER. In September 2021, the Spanish Ministry of Science and Innovation has awarded Tetraneuron the INNOVATIVE SME seal. Consequently, the company has been registered in the official public register of Innovative SMEs. By awarding this distinction, whose objective is to reward and highlight SMEs activities in regards to R&D and innovation, the Ministry is officially recognizing the innovative and pioneering nature of Tetraneutron’s research in the field of Alzheimer’s disease.
Therapeutic area: Neurodegenerative diseases